BMO Capital Reiterates Outperform Rating on Disc Medicine (IRON) Jan 29, 2026 04:49AM
BMO on Disc Medicine (IRON) Post Mgmt Call: 'management indicated that FDA has given no indication that the NDA review process is currently at risk' Dec 19, 2025 02:14PM
BMO Capital Reiterates Outperform Rating on Disc Medicine (IRON) Jun 17, 2025 10:04AM
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants Jan 22, 2025 09:35PM
Disc Medicine (IRON) PT Raised to $112 at BMO Capital Nov 5, 2024 07:57AM


Jun 17, 2024 08:21AM Disc Medicine (IRON) PT Raised to $70 at BMO Capital
Jun 13, 2024 09:41AM BMO Capital Reiterates Outperform Rating on Disc Medicine (IRON)
Apr 2, 2024 06:42AM Disc Medicine (IRON) PT Lowered to $50 at BMO Capital
Feb 29, 2024 07:28AM Disc Medicine (IRON) PT Raised to $80 at BMO Capital
Jun 22, 2023 04:15PM Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jun 14, 2023 04:57AM Disc Medicine (IRON) Prices Upsized $137.2M Share and Warrant Offering at $49/sh
Jun 13, 2023 10:39PM Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Jun 12, 2023 04:00PM Disc Medicine (IRON) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Jun 12, 2023 04:00PM Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants